Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-29
2006-08-29
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S415000, C548S452000, C548S469000, C548S470000
Reexamination Certificate
active
07098235
ABSTRACT:
Prodrugs of glycogen phosphorylase inhibiting compounds are provided which are useful in treating diabetes, having the formula Iin-line-formulae description="In-line Formulae" end="lead"?G(—O2CR′)m(—OH)n(—O2C(CH2)pCH3)qIin-line-formulae description="In-line Formulae" end="tail"?wherein G is a C3to C5branched or straight carbon chain and (—O2CR′), (—OH) and (—O2C(CH2)pCH3) are attached to any available carbon atom along G;—O2CR′ is a fragment of a compound of formula Ibwhere W is a bicyclic heteroaryl; m, n, p, q, X, Y, Z, R1and R2are as defined herein, as exemplified byFurther provided are pharmaceutical compositions and methods for treating diabetes and related diseases employing the above compounds above, either alone or in combination with another therapeutic agent.
REFERENCES:
patent: 3674836 (1972-07-01), Creger
patent: 3983140 (1976-09-01), Endo et al.
patent: 4027009 (1977-05-01), Grier et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4448784 (1984-05-01), Glamkowski et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4499289 (1985-02-01), Baran et al.
patent: 4512988 (1985-04-01), Weller, III et al.
patent: 4613610 (1986-09-01), Wareing
patent: 4647576 (1987-03-01), Hoefle et al.
patent: 4681893 (1987-07-01), Roth
patent: 4686237 (1987-08-01), Anderson
patent: 4692522 (1987-09-01), Parsons et al.
patent: 4755509 (1988-07-01), Teulon
patent: 4871721 (1989-10-01), Biller
patent: 4924024 (1990-05-01), Biller
patent: 5006530 (1991-04-01), Angerbauer et al.
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5206235 (1993-04-01), Fisher et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5273995 (1993-12-01), Roth
patent: 5354772 (1994-10-01), Kathawala
patent: 5385929 (1995-01-01), Bjorge et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher et al.
patent: 5506219 (1996-04-01), Robl
patent: 5541204 (1996-07-01), Sher et al.
patent: 5545735 (1996-08-01), Bochis et al.
patent: 5552397 (1996-09-01), Karanewsky et al.
patent: 5594006 (1997-01-01), Sakamoto et al.
patent: 5595872 (1997-01-01), Wetterau, II et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5614492 (1997-03-01), Habener
patent: 5652363 (1997-07-01), Khanna et al.
patent: 5686104 (1997-11-01), Mills et al.
patent: 5691322 (1997-11-01), Robl
patent: 5712279 (1998-01-01), Biller et al.
patent: 5712396 (1998-01-01), Magnin et al.
patent: 5719278 (1998-02-01), Albright et al.
patent: 5739135 (1998-04-01), Biller et al.
patent: 5753675 (1998-05-01), Wattanasin
patent: 5760246 (1998-06-01), Biller et al.
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5789587 (1998-08-01), Fisher et al.
patent: 5827875 (1998-10-01), Dickson, Jr. et al.
patent: 5849918 (1998-12-01), Esser et al.
patent: 5885983 (1999-03-01), Biller et al.
patent: 5962440 (1999-10-01), Sulsky
patent: 6017926 (2000-01-01), Askew et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6107329 (2000-08-01), Hoover et al.
patent: 0 160 546 (1985-11-01), None
patent: 0 221 025 (1987-05-01), None
patent: 0 107 095 (1987-09-01), None
patent: 0 142 146 (1988-08-01), None
patent: 0 416 740 (1991-03-01), None
patent: 0 978 279 (2000-02-01), None
patent: 0978279 (2000-02-01), None
patent: 1 088 824 (2004-01-01), None
patent: 2 596 393 (1987-10-01), None
patent: 2 205 837 (1988-12-01), None
patent: 2000-256318 (2000-09-01), None
patent: WO 86/03488 (1986-06-01), None
patent: WO 86/07054 (1986-12-01), None
patent: WO 93/14067 (1993-07-01), None
patent: WO 96/36596 (1996-11-01), None
patent: WO 96/38144 (1996-12-01), None
patent: WO 96/39384 (1996-12-01), None
patent: WO 96/39385 (1996-12-01), None
patent: WO 97/12613 (1997-04-01), None
patent: WO 97/12615 (1997-04-01), None
patent: WO 97/21993 (1997-06-01), None
patent: WO 97/43268 (1997-11-01), None
patent: WO 99/00353 (1999-01-01), None
patent: WO 99/26659 (1999-06-01), None
patent: WO 99/38501 (1999-08-01), None
patent: WO 99/46272 (1999-09-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/67278 (1999-12-01), None
patent: WO 99/67279 (1999-12-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO 00/59506 (2000-10-01), None
patent: WO 01/00586 (2001-01-01), None
patent: WO 01/21602 (2001-03-01), None
patent: WO 01/21602 (2001-03-01), None
patent: WO 01/27128 (2001-04-01), None
Murakami et al., “1,3-Disubstituted Benzazepines as Novel . . . ”, J. Med. Chem 1999, 42, 2621-2632.
Yameda et al., “A potent Dipeptide Inhibitor of Dipeptidyl Peptidase IV”, Bioorganic & Medicinal Letters, 8, (1998) 1537-1540.
Albright, J.D. et al., “Synthesis of 1,4,5,6-Tetrahydropyrazolo[3,4,-d]pyrido[3,2-b]azepine”, J. Heterocyclic Chem., vol. 37, pp. 41-46 (2000).
Aranyos, A. et al., “Novel Electron-Rich Bulky Phosphine Ligands Facilitate the Palladium-Catalyzed Preparation of Diaryl Ethers”, J. Am. Chem. Soc., vol. 121, No. 18, pp. 4369-4378 (1999).
Arbeeny, C. et al., “The Metabolic Syndrome: From Pathophysiology to Novel Treatment Strategies”, Curr. Med. Chem.—Imm., Endoc & Metab Agents., vol. 1, No. 1, pp. 1-24 (2001).
Armstrong, III, J.D. et al., “An Efficient Asymmetric Synthesis of (R)-3-Amino-2,3,4,5-tetrahydro-1H-[1]benzazepin-2-one”, Tetrahedron Letters, vol. 35, No. 20, pp. 3239-3242 (1994).
Ashworth, D.M. et al., “2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Bioorganic & Medicinial Chemistry Letters, vol. 6, No. 10, pp. 1163-1166 (1996).
Ashworth, D.M. et al., “4-Cyanothiazolidides as Very Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Bioorganic & Medicinial Chemistry Letters, vol. 6, No. 22, pp. 2745-2748 (1996).
Ball, J.B. et al., “Synthesis and Conformational Analyses of Some 3-Amino-2,5-dioxo-2,3,4,5-tetrahydro-1H-1-benzazepine Derivatives: X-Ray Crystal Structure of 3S-3-[[(1,1-Dimethylethoxy)carbonyl]amino]-2,5-dioxo-2,3,4,5-tetrahydro-1H-1-benzazepine”, J. Heterocyclic Chem. vol. 27, pp. 279-286 (1990).
Bebernitz, G.R. et al., “Reduction in Glucose Levels in STZ Diabetic Rats by 4-(2,2-Dimethyl-1-oxopropyl)benzoic Acid: A Prodrug Approach for Targeting the Liver”, J. Med. Chem. vol. 44, No. 4, pp. 512-523 (2001).
Bell, I.M. et al., “Development of Orally Active Oxytocin Antagonists: Studies on 1-(1-(4-[1-(2-Methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2-methoxybenzoyl)piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and Related Pyridines”, J. Med. Chem., vol. 41, No. 12, pp. 2146-2163 (1998).
Berg-Nielsen, K. et al., “Amino-Claisen Rearrangement of Vinyl Propargylamines and Pyrindane Synthesis from a Divinyl Ketone”, Acta Chemica Scandinavica B, vol. 32, pp. 553-556 (1978).
Biller, S.A. et al., “Isoprenoid (Phosphinylmethyl)phosphonates as Inhibitors of Squalene Synthetase”, Journal of Medicinal Chemistry, vol. 31, No. 10, pp. 1869-1871 (1988).
Biller, S.A. et al., “Squalene Synthase Inhibitors”, Current Pharmaceutical Design, vol. 2, No. 1, pp. 1-40 (1996).
Bundgaard, H., Chapter 5: “Design and Application of Prodrugs”, A Textbook of Drug Design and Development, Harwood Academic Publishers, publ., Krogsgaard-Larsen, P. et al., eds., pp. 113-191 (1991).
Bundgaard, H., ed., Design of Prodrugs, Elsevier Science Publishers B.V., publ. (1985) (table of contents).
Caprathe, B.W. et al., “Dopamine Autoreceptor Agonists as Potential Antipsychotics. 3. 6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine”, J. Med. Chem., vol. 34, No. 9, pp. 2736-2746 (1991).
Capson, T.L., “Synthesis and Evaluation of Ammonium Analogs of Carbocationic Intermediates in Squalene Biosynthesis”, dissertation, Department of Medicinal Chemistry, University of Utah, pp. iv-v, Table of Contents, 16-17, 40-43, 48-51, Summary (Jun. 1
Ellsworth Bruce A.
Sher Philip M.
Bristol-Myers Squibb Co.
O'Brien Maureen P.
Rodney Burton
Ward Paul V.
Wilson James O.
LandOfFree
Triglyceride and triglyceride-like prodrugs of glycogen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triglyceride and triglyceride-like prodrugs of glycogen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triglyceride and triglyceride-like prodrugs of glycogen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3707467